Takeda Pharmaceutical Co Ltd (TAK)
13.34
-0.04
(-0.26%)
USD |
NYSE |
May 06, 15:30
Takeda Pharmaceutical Research and Development Expense (Quarterly): 1.269B for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 1.269B |
| September 30, 2023 | 1.273B |
| June 30, 2023 | 1.186B |
| March 31, 2023 | 1.218B |
| December 31, 2022 | 1.239B |
| September 30, 2022 | 1.116B |
| June 30, 2022 | 1.108B |
| March 31, 2022 | 1.236B |
| December 31, 2021 | 1.129B |
| September 30, 2021 | 1.196B |
| June 30, 2021 | 1.119B |
| March 31, 2021 | 1.070B |
| December 31, 2020 | 1.126B |
| September 30, 2020 | 1.113B |
| June 30, 2020 | 992.67M |
| March 31, 2020 | 1.279B |
| December 31, 2019 | 1.128B |
| September 30, 2019 | 1.058B |
| June 30, 2019 | 1.063B |
| March 31, 2019 | 1.266B |
| December 31, 2018 | 687.08M |
| September 30, 2018 | 712.95M |
| June 30, 2018 | 659.82M |
| March 31, 2018 | 819.03M |
| December 31, 2017 | 722.19M |
| Date | Value |
|---|---|
| September 30, 2017 | 715.92M |
| June 30, 2017 | 681.23M |
| March 31, 2017 | 778.36M |
| December 31, 2016 | 658.24M |
| September 30, 2016 | 736.82M |
| June 30, 2016 | 708.78M |
| March 31, 2016 | 766.50M |
| December 31, 2015 | 734.59M |
| September 30, 2015 | 641.91M |
| June 30, 2015 | 657.81M |
| March 31, 2015 | 1.115B |
| December 31, 2014 | 810.66M |
| September 30, 2014 | 782.80M |
| June 30, 2014 | 735.70M |
| March 31, 2014 | 997.18M |
| December 31, 2013 | 827.52M |
| September 30, 2013 | 775.17M |
| June 30, 2013 | 802.38M |
| March 31, 2013 | 974.55M |
| December 31, 2012 | 947.03M |
| September 30, 2012 | 963.95M |
| June 30, 2012 | 984.03M |
| March 31, 2012 | |
| December 31, 2011 | 914.09M |
| September 30, 2011 | 788.48M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
992.67M
Minimum
Jun 2020
1.279B
Maximum
Mar 2020
1.154B
Average
1.128B
Median
Dec 2019
Research and Development Expense (Quarterly) Benchmarks
| Astellas Pharma Inc | 503.80M |
| Nxera Pharma Co Ltd | 20.74M |
| PeptiDream Inc | 6.067M |
| Stemcell Holdings Inc | -- |
| Healios KK | 5.235M |